FDA
-
-
-
-
-
-
-
Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting
-
-
-
-
-
-
-
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
-
-
-
-
-
-
-
Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell T
-
-
-
-
-
-
-
Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Caribou Bioscience (CRBU) Appoints Tina Albertson, MD, PhD, as Chief Medical Officer
-
-
-
-
-
-
-
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

